Regencell Investors Urged to Seek Lead Role in Securities Class Action by June 23

Overview

• Plaintiff law firms on Monday and Tuesday issued notices urging Regencell Bioscience investors to move for lead-plaintiff status by June 23, 2026 in a filed federal class action.
• The lawsuit covers purchases from October 28, 2024 through October 31, 2025 and claims the company misled investors by not disclosing susceptibility to manipulation and sharp price swings.
• The complaint says the undisclosed volatility exposed shareholders to heavy losses and increased the chance of regulatory scrutiny and penalties for the company.
• Regencell later disclosed a U.S. Justice Department subpoena into trading of its shares in an SEC filing, and the stock fell 18.6% to close at $13.56 the next trading day.
• The notices emphasize that no class is certified, investors are not represented unless they retain counsel, and any recovery is uncertain under contingency-fee arrangements.